Search
Dexamethasone Treatment Options in United Kingdom
A collection of 187 research studies where Dexamethasone is the interventional treatment. These studies are located in the United Kingdom . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
121 - 132 of 187
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Completed
This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis. The trial begins with a dose escalation phase, in which the maximum tolerated and recommended dose will be determined. The trial will then open into an expansion phase in which the combination efficacy is assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2021
Locations: Derriford Hospital, Plymouth, Devon +13 locations
Conditions: Amyloidosis
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
Completed
The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line platinum-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2021
Locations: Clearview Cancer Institute /ID# 155873, Huntsville, Alabama +194 locations
Conditions: Small Cell Lung Cancer
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Completed
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
12/11/2020
Locations: University Chicago Hospital Dept. of Univ of Chicago (2), Chicago, Illinois +7 locations
Conditions: Multiple Myeloma, Renal Insufficiency
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Completed
Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2020
Locations: 1107, Tuscaloosa, Alabama +81 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
Completed
A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/26/2020
Locations: Research Site, Chicago, Illinois +23 locations
Conditions: High-risk Diffuse Large B-Cell Lymphoma
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Completed
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore, clinical experience in advanced multiple myeloma (MM) pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2020
Locations: Novartis Investigative Site, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
Unknown
This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma. Participants will either receive ixazomib with cyclophosphamide and dexamethasone or cyclophosphamide and dexamethasone alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: Queen Elizabeth Medical Centre, Birmingham, Not set +17 locations
Conditions: Multiple Myeloma
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
Completed
The primary objective is to compare the time to progression (TTP) of three daily doses of thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory multiple myeloma (MM) patients and to subsequently select the optimum thalidomide dose in terms of median TPP and toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2019
Locations: Clinic of Haematology, University Multiprofiled Hospital for Active Treatment "G. Stranski", Pleven, Not set +85 locations
Conditions: Multiple Myeloma
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/07/2019
Locations: Not set, Greenbrae, California +83 locations
Conditions: Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Completed
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: University of AL Birmingham, Birmingham, Alabama +287 locations
Conditions: Multiple Myeloma
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
Completed
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2019
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona +56 locations
Conditions: Multiple Myeloma
Enhanced Recovery After Cardiac Surgery
Unknown
Enhanced Recovery Protocols (ERPs or bundles) have been established in many surgical specialties (such as colon cancer and orthopaedic joint surgeries) for several years in hospitals worldwide. The principles of Enhanced Recovery Protocols are those of early mobilization and restoration of normal function as soon as possible after surgery. These principles are achieved by use of alternate pain control regimens and removing invasive lines and drains as soon as possible. The benefits of ERPs are i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2019
Locations: James Cook University Hospital, Middlesbrough, Teeside
Conditions: Cardiac Surgery, Coronary Artery Disease, Aortic Valve Disease, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Root Dilatation
121 - 132 of 187
